Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome

Journal of Investigative Dermatology

Volumn 134, Issue 10, 2014, Pages 2639-2647

  Van Der Fits, Leslie ^a   Out Luiting, Jacoba J ^a   Tensen, Cornelis P ^a   Zoutman, Willem H ^a   Vermeer, Maarten H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; INTERLEUKIN 21; MICRORNA 21; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE PIM 1; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST 1; UNCLASSIFIED DRUG; HYBRID PROTEIN; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN DERIVATIVE; STAT3 PROTEIN, HUMAN; STATTIC; SULFOXIDE;

AGED; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF DETECTION; MALE; POSITIVE FEEDBACK; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SEZARY SYNDROME; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIC S-OXIDES; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-21; RECOMBINANT FUSION PROTEINS; SEZARY SYNDROME; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84922394379     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.199     Document Type: Article

References (42)

1. Brenne AT, Ro TB, Waage A et al. (2002) Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99:3756-62
2. Bromberg JF, Wrzeszczynska MH, Devgan G et al. (1999) Stat3 as an oncogene. Cell 98:295-303
3. Caprioli F, Sarra M, Caruso R et al. (2008) Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 180:1800-7
4. Chen X, Xu H, Yuan P et al. (2008) Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133:1106-17
5. Cheng GZ, Zhang WZ, Sun M et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283:14665-73
6. Cornelissen C, Luscher-Firzlaff J, Baron JM et al. (2012) Signaling by IL-31 and functional consequences. Eur J Cell Biol 91:552-66
7. Davis ID, Skak K, Smyth MJ et al. (2007) Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 13:6926-32
8. Dien Bard J, Gelebart P, Anand M et al. (2009) IL-21 contributes to JAK3/ STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 175:825-34
9. Dummer R, Heald PW, Nestle FO et al. (1996) Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 88:1383-9
10. Eriksen KW, Kaltoft K, Mikkelsen G et al. (2001) Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787-93
11. Frank DA (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251:199-210
12. Gupta M, Han JJ, Stenson M et al. (2012) Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26:1356-64
13. Hutchins AP, Poulain S, Miranda-Saavedra D (2012) Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages. Blood 119:e110-9
14. Kaltoft K, Bisballe S, Rasmussen HF et al. (1987) A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279:293-8
15. Kwon H, Thierry-Mieg D, Thierry-Mieg J et al. (2009) Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31:941-52
16. Lamprecht B, Kreher S, Anagnostopoulos I et al. (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112:3339-47
17. Loffler D, Brocke-Heidrich K, Pfeifer G et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110: 1330-3
18. Marzec M, Halasa K, Kasprzycka M et al. (2008) Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4 cutaneous T-cell lymphoma cells. Cancer Res 68:1083-91
19. Masciocchi D, Gelain A, Villa S et al. (2011) Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Med Chem 3:567-97
20. Monteleone G, Pallone F, Macdonald TT (2008) Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 29:290-4
21. Monteleone G, Pallone F, Macdonald TT (2009) Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 20:185-91
22. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178:2623-9
23. Nielsen M, Kaestel CG, Eriksen KW et al. (1999) Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 13:735-8
24. Ohmatsu H, Sugaya M, Suga H et al. (2012) Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol 92:282-3
25. Olsen E, Vonderheid E, Pimpinelli N et al. (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 1713-22
26. Schust J, Sperl B, Hollis A et al. (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235-42
27. Spitzner M, Roesler B, Bielfeld C et al. (2014) STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer 134:997-1007
28. Tiffon C, Adams J, van der Fits L et al. (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 162:1590-602
29. van der Fits L, Out-Luiting JJ, van Leeuwen MA et al. (2012) Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sezary syndrome. J Invest Dermatol 132:440-7
30. van der Fits L, van Kester MS, Qin Y et al. (2011) MicroRNA-21 expression in CD4 T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol 131:762-8
31. van Doorn R, Dijkman R, Vermeer MH et al. (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 64:5578-86
32. van Kester MS, Borg MK, Zoutman WH et al. (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumorstage mycosis fungoides. J Invest Dermatol 132:2050-9
33. van Kester MS, Out-Luiting JJ, von dem Borne PA et al. (2008) Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J Invest Dermatol 128:1691-5
34. Vermeer MH, van Doorn R, Dijkman R et al. (2008) Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res 68:2689-98
35. Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85
36. Yang J, Chatterjee-Kishore M, Staugaitis SM et al. (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939-47
37. Yang J, Stark GR (2008) Roles of unphosphorylated STATs in signaling. Cell Res 18:443-51
38. Yoon JS, Newton SM, Wysocka M et al. (2008) IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sezary syndrome. J Invest Dermatol 128:473-80
39. Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4:97-105
40. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51
41. Zhang C, Li B, Gaikwad AS et al. (2008) Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J Invest Dermatol 128:2728-35
42. Zhang Q, Nowak I, Vonderheid EC et al. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93:9148-53